DDB2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07247(DDB2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07247(DDB2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The DDB2 antibody targets the Damage-specific DNA-binding protein 2 (DDB2), a critical component of the nucleotide excision repair (NER) pathway involved in recognizing UV-induced DNA lesions. DDB2 forms a heterodimer with DDB1 (DDB1-DDB2 complex) to identify cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts, facilitating their repair by recruiting downstream NER factors. Mutations in the DDB2 gene are linked to xeroderma pigmentosum (XP), a genetic disorder characterized by extreme UV sensitivity and heightened skin cancer risk. DDB2 also plays roles beyond DNA repair, including regulating apoptosis, cell cycle progression, and transcriptional activation.

Antibodies against DDB2 are widely used in research to study DNA damage response mechanisms, protein interactions, and DDB2's involvement in diseases like cancer. They enable detection of DDB2 expression levels via techniques such as Western blotting, immunofluorescence, and immunohistochemistry, aiding in investigations of its subcellular localization, post-translational modifications, and functional dynamics under stress conditions. Commercial DDB2 antibodies are available as monoclonal or polyclonal variants, often validated for specificity and sensitivity in human or murine models. Understanding DDB2's role through antibody-based assays contributes to insights into genomic stability maintenance and potential therapeutic strategies targeting DNA repair pathways.